Search Result

Results for "

HDAC2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amyloid-β (1) Apoptosis (35) Autophagy (17) Bcl-2 Family (1) Caspase (1) CCR (1) CDK (4) Endogenous Metabolite (10) FGFR (1) Filovirus (2) HDAC (85) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (1) Histone Methyltransferase (2) HIV (11) HPV (2) iGluR (1) Isotope-Labeled Compounds (4) Microtubule/Tubulin (2) Mitophagy (12) Necroptosis (1) NF-κB (1) Notch (10) Organoid (2) Parasite (2) PARP (1) Phosphatase (1) PI3K (2) Proteasome (1) Reactive Oxygen Species (2) SHP2 (1) Topoisomerase (2) VEGFR (1)
By Research Areas:	Cancer (73) Cardiovascular Disease (1) Endocrinology (1) Infection (8) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (12)

By Targets:

Akt (1)

Amyloid-β (1)

Apoptosis (35)

Autophagy (17)

Bcl-2 Family (1)

Caspase (1)

CCR (1)

CDK (4)

Endogenous Metabolite (10)

FGFR (1)

Filovirus (2)

HDAC (85)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (1)

Histone Methyltransferase (2)

HIV (11)

HPV (2)

iGluR (1)

Isotope-Labeled Compounds (4)

Microtubule/Tubulin (2)

Mitophagy (12)

Necroptosis (1)

NF-κB (1)

Notch (10)

Organoid (2)

Parasite (2)

PARP (1)

Phosphatase (1)

PI3K (2)

Proteasome (1)

Reactive Oxygen Species (2)

SHP2 (1)

Topoisomerase (2)

VEGFR (1)

By Research Areas:

Cancer (73)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (8)

Inflammation/Immunology (3)

Metabolic Disease (3)

Neurological Disease (12)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	HDAC Amyloid-β	Neurological Disease Cancer
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-117583

cis-BG47	HDAC Histone Methyltransferase	Neurological Disease
cis-BG47 is an cis-isomer of BG47, BG47 is a prototypical histone deacetylases *HDAC1* and *HDAC2* selective, optoepigenetic probe. BG47 can bind to and competitively inhibits the deacetylase activity of *HDAC* targets upon a light-induced trans-to-cis isomerization, and increases Histone Methyltransferase H3K9 acetylation. cis-BG47 can be used for neurological disease research .

HY-151248

HDAC2-IN-1	HDAC	Neurological Disease
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive *HDAC2* inhibitor with an IC₅₀ of 0.5 μM . HDAC2-IN-1 also inhibits *HDAC1* and *HDAC8* with IC₅₀s of 1.61 μM and 0.98 μM, respectively .

HY-157388

CARM1/HDAC2-IN-1	Histone Methyltransferase HDAC	Cancer
CARM1/HDAC2-IN-1 (compound CH-1) is a dual inhibitor against CARM1 and *HDAC2, with IC₅₀* values of 3.71 nM and 4.07 nM, respectively. CARM1/HDAC2-IN-1 possesses antitumor activity .

HY-110264

MI-192	HDAC Apoptosis	Neurological Disease Cancer
MI-192 is a selective *HDAC2* and *HDAC3* inhibitor with IC₅₀s of 30 nM and 16 nM, respectively. MI-192 is more selective for HDAC2/3 than other HDAC isomers.MI-192 induces myeloid leukaemic cells apoptosis. Anticaner and neuroprotective activities .

HY-100719

BRD-6929	HDAC HIV	Infection Cardiovascular Disease
BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase *HDAC1* and *HDAC2* inhibitor with IC₅₀ of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with K_i of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research .

HY-139650

HDAC1/2-IN-3

HDAC Cancer

HDAC1/2-IN-3 is a HDAC1 and HDAC2 inhibitor with IC₅₀ values 0-5 and 5-10 nM, respectively.

HDAC1/2-IN-3	HDAC	Cancer
HDAC1/2-IN-3 is a **HDAC1 and HDAC2** inhibitor with IC₅₀ values 0-5 and 5-10 nM, respectively.

HY-12163

Entinostat 35+ Cited Publications MS-275; SNDX-275	HDAC Autophagy Apoptosis	Cancer
Entinostat is an oral and selective class I *HDAC* inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for *HDAC1, HDAC2, and HDAC3*, respectively.

HY-146153

HDAC-IN-40	HDAC	Cancer
HDAC-IN-40 is a potent alkoxyamide-based *HDAC* inhibitor with K_i values of 60 nM and 30 nM for *HDAC2* and *HDAC6, respectively. HDAC*-IN-40 had antitumor effects .

HY-101780

Tinostamustine 3 Publications Verification EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan *HDAC* inhibitor; inhibits *HDAC6, HDAC1, HDAC2* and *HDAC3* with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .

HY-151443

HDAC-IN-47	HDAC	Cancer
HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC₅₀s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo .

HY-16026

Ricolinostat 20+ Cited Publications ACY-1215; Rocilinostat	HDAC Apoptosis	Cancer
Ricolinostat (ACY-1215) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits *HDAC1, HDAC2, and HDAC3* with IC₅₀s of 58, 48, and 51 nM, respectively.

HY-19327

ACY-738 2 Publications Verification	HDAC	Cancer
ACY-738 is a potent, selective and orally-bioavailable *HDAC6* inhibitor, with an IC₅₀ of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC₅₀s of 94, 128, and 218 nM.

HY-151896

HDAC6-IN-14

HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .
HY-112908

RTS-V5

HDAC Proteasome Cancer

RTS-V5 is a dual HDAC/proteasome inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

RTS-V5	HDAC Proteasome	Cancer
RTS-V5 is a dual *HDAC/proteasome* inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.

HY-12163S

Entinostat-d4 MS-275-d₄; SNDX-275-d₄	Apoptosis Autophagy HDAC	Cancer
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-156422

KPZ560	HDAC	Neurological Disease Cancer
KPZ560 is a potent inhibitor of *HDAC1 and HDAC2, with IC₅₀s of 12 nM and 68 nM, respectively. KPZ560 can increase in the spine density of granule neuron dendrites of mice and inhibitor* cell growth of breast cancer cell line MCF .

HY-111400

SR-4370

HDAC Cancer

SR-4370 is an inhibitor of HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively.

SR-4370	HDAC	Cancer
SR-4370 is an inhibitor of *HDAC, with IC₅₀s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC*6, respectively.

HY-104008

ACY-957 1 Publications Verification	HDAC	Others
ACY-957 is an orally active and selective inhibitor of *HDAC1* and *HDAC2, with IC₅₀s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC*4/5/6/7/8/9 .

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-152174

HDAC-IN-52	HDAC	Cancer
HDAC-IN-52 is a pyridine-containing *HDAC* inhibitor, with IC₅₀s of 0.189, 0.227, 0.440 and 0.446 μM for *HDAC1, HDAC2, HDAC3, and HDAC10, respectively. HDAC*-IN-52 can be used for the research of cancer .

HY-18712

BG45 2 Publications Verification	HDAC Apoptosis Caspase	Cancer
BG45 is a potent *HDAC3* inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis .

HY-15994

Citarinostat 3 Publications Verification ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .

HY-100748

Zabadinostat 1 Publications Verification CXD101	HDAC	Cancer
Zabadinostat (CXD101) is a potent, selective and orally active class I *HDAC* inhibitor with IC₅₀s of 63 nM, 570 nM and 550 nM for *HDAC1, HDAC2* and *HDAC3, respectively. Zabadinostat has no activity against HDAC* class II. Zabadinostat has antitumor activity .

HY-147840

HDAC-IN-41	HDAC	Cancer
HDAC-IN-41 (Compound 7c) is a selective, orally active class I *HDAC* inhibitor with IC₅₀ values of 0.62, 1.46 and 0.62 μM against HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-41 shows NO releasing activity .

HY-155840

KH16	HDAC Apoptosis	Cancer
KH16 is a potent and low nanomolar HDAC inhibitor. KH16 is against class I HDACs HDAC1, HDAC2, and HDAC3, with IC₅₀ ?values ranging from 6 to 34 nM. KH16 induces cell apoptosis and is against tumor cells with various gene expression patterns .

HY-161050

YSR734	HDAC Apoptosis	Cancer
YSR734 (Compound 21) is a covalent *HDAC* inhibitor with IC₅₀ values of 110 nM, 154 nM, and 143 nM for *HDAC1, HDAC2, and HDAC3, respectively. YSR734 can induce apoptosis* in leukemia cells. YSR734 can induce myoblast differentiation and is used in the study of Duchenne muscular dystrophy .

HY-18613

CAY10603 4 Publications Verification BML-281	HDAC	Cancer
CAY10603 (BML-281) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM.

HY-16012

Domatinostat tosylate 3 Publications Verification 4SC-202	HDAC Apoptosis	Cancer
Domatinostat tosylate (4SC-202) is a selective class I *HDAC* inhibitor with IC₅₀ of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).

HY-163430

HDAC-IN-71	HDAC Apoptosis	Cancer
HDAC-IN-71 (Compound 17q) is a potent *HDAC* inhibitor with IC₅₀ values of 12.6, 14.1, 20, 3, and 72 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. HDAC-IN-71 induces apoptosis and can be used in cancer research .

HY-18998

LMK-235 15+ Cited Publications	HDAC	Cancer
LMK-235 is a potent and selective *HDAC4/5* inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC₅₀s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

HY-16012A

Domatinostat 3 Publications Verification 4SC-202 free base	HDAC Apoptosis	Cancer
Domatinostat (4SC-202 free base) is a selective class I *HDAC* inhibitor with IC₅₀ of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).

HY-15433A

Quisinostat dihydrochloride 5+ Cited Publications JNJ-26481585 dihydrochloride	HDAC Apoptosis Autophagy	Cancer
Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally available, potent pan-HDAC inhibitor with IC₅₀s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity .

HY-145688

HDAC-IN-33	HDAC	Cancer
HDAC-IN-33 is a potent *HDAC* inhibitor with IC₅₀s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-151897

HDAC-IN-49	HDAC	Cancer
HDAC-IN-49 is a potent unselective *HDAC* (HDAC) inhibitor with IC₅₀s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .

HY-18700

BRD73954 3 Publications Verification	HDAC	Cancer
BRD73954 is a potent *HDAC* inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC₅₀ values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin .

HY-145687

HDAC-IN-32	HDAC	Cancer
HDAC-IN-32 is a potent *HDAC* inhibitor with IC₅₀s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-162377

HDAC-IN-70	HDAC Apoptosis Necroptosis	Cancer
HDAC-IN-70 (compound 4c) is *HDAC6* inhibitor with the IC₅₀ values of 64.13 nM, 166 nM, 618 nM and 253 nM for HDAC6, HDAC1, HDAC2 and HDAC4, respectively. HDAC-IN-70 induces cell cycle arrest, apoptosis and necrotic. HDAC-IN-70 can be used for study of leukemia .

HY-144332

PHD2/HDACs-IN-1	HDAC HIF/HIF Prolyl-Hydroxylase	Cancer
PHD2/HDACs-IN-1 is a potent *PHD2/HDACs* hybrid inhibitor (IC₅₀s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .

HY-15433

Quisinostat 5+ Cited Publications JNJ-26481585	HDAC Apoptosis Autophagy	Cancer
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC₅₀ values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity . Quisinostat can induce autophagy in neuroblastoma cells .

HY-149946

HDAC-IN-57	HDAC Apoptosis Histone Demethylase
HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC₅₀s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC₅₀ of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity .

HY-12164

Mocetinostat 10+ Cited Publications MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for *HDAC1, HDAC2, HDAC3* and *HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC*8.

HY-117709

BRD6688	HDAC	Neurological Disease
BRD6688 is a selective *HDAC2* inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .

HY-10585AS1

Valproic acid-d14 sodium Sodium Valproate-d₁₄ sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-15149

Romidepsin 40+ Cited Publications FK 228; FR 901228; NSC 630176	HDAC Apoptosis	Cancer
Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively . Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis .

HY-147873

NMDAR/HDAC-IN-1	iGluR HDAC	Neurological Disease
NMDAR/HDAC-IN-1 (Compound 9d) is a dual NMDAR and *HDAC* inhibitor with a K_i of 0.59 μM for NMDAR and IC₅₀ values of 2.67, 8.00, 2.21, 0.18 and 0.62 μM for HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8, respectively. NMDAR/HDAC-IN-1 efficiently penetrates the blood brain barrier .

HY-10221

Vorinostat Maximum Cited Publications 87 Publications Verification SAHA; Suberoylanilide hydroxamic acid	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Infection Cancer
Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), *HDAC6* and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .

HY-13522

Fimepinostat 5+ Cited Publications CUDC-907	PI3K HDAC Apoptosis	Cancer
Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II *HDAC* enzymes with an IC₅₀ of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.

HY-100384

NKL 22 1 Publications Verification	HDAC	Neurological Disease
NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC₅₀ of 199 and 69 nM for *HDAC1* and *HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2*/4/5/7/8 (IC₅₀≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice .

HY-10585AS

Valproic acid-d7 sodium Sodium Valproate-d₇(sodium)	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	Alkaloids Structural Classification Microorganisms other families Classification of Application Fields Other Alkaloids Source classification Plants Disease Research Fields Cancer	HDAC Amyloid-β
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-10585A

Valproic acid sodium Maximum Cited Publications 33 Publications Verification Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585

Valproic acid Maximum Cited Publications 33 Publications Verification Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-N2609

7,4'-Dihydroxyflavone 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Leguminosae Source classification Phenols Polyphenols Plants Disease Research Fields Glycyrrhiza uralensis Fisch. Endocrinology	CCR NF-κB
7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC₅₀=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production . 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC₅₀ value of 1.4 µM .

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Chemical Structure

HY-12163S

Entinostat-d4
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks